Abstract
Despite the effectiveness of PD-L1 inhibitors in combination with platinum-based chemotherapy as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC), most patients still have disease progression and prognosis remains poor. In the IMpower133 study, the addition of atezolizumab (monoclonal anti-PD-L1 antibody) to chemotherapy improved median overall survival (mOS) to 12.3 months compared with 10.3 months in the chemotherapy plus placebo arm (HR 0.70; 95% CI: 0.54, 0.91; P=0.007; Horn et al, 2018).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
